News Focus
News Focus
Followers 24
Posts 3955
Boards Moderated 0
Alias Born 07/20/2006

Re: floblu14 post# 10592

Thursday, 06/06/2013 9:54:22 AM

Thursday, June 06, 2013 9:54:22 AM

Post# of 20689
UBS likes the risk/reward profile for Momenta Pharmaceuticals (MNTA +4%) as analyst Ami Fadi...

June 6, 9:30 AM ET
UBS likes the risk/reward profile for Momenta Pharmaceuticals (MNTA +4%) as analyst Ami Fadi says management's rhetoric indicates approval for generic Copaxone may come in time for 2015 patent expirations.

http://seekingalpha.com/currents/post/1068791